SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is facing significant selling pressure as investors scrutinize the company's aggressive AI infrastructure spending and its impact on free cash flow despite strong ad revenue growth. The community is actively debating whether these heavy capital expenditures are a necessary strategic investment for long-term dominance or an unsustainable burden on margins that threatens shareholder value.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following the broad UAE approval of Anktiva for bladder and lung cancer, sparking community optimism about the company's expanding global regulatory footprint. Investors are actively debating the timing of revenue growth and potential catalysts, while maintaining a cautious eye on upcoming earnings and significant short interest.

Stellantis NV engages in the designing, engineering, manufacturing, distributing, and selling of vehicles and components. It offers its products under the Abarth, Alfa Romeo, Chrysler, Citroën, Dodge, DS Automobiles, Fiat, Jeep, Lancia, Maserati, Opel, Peugeot, Ram Trucks, Vauxhall, Free2move, and Leasys brands. The company was founded on April 1, 2014 and is headquartered in Hoofddorp, the Netherlands.

Stellantis N.V

Stellantis is trending as investors weigh an aggressive turnaround strategy, including a 70 billion investment plan and a pivot back to core brands, against concerns over weak North American margins and inventory levels. Community discussion remains heavily polarized between bulls betting on a deep-value cyclical recovery and skeptics pointing to manufacturing challenges and intensifying global competition.

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Rigel Pharmaceuticals

Rigel Pharmaceuticals is currently a focal point for investors as they transition from a hematology-focused firm to an oncology growth company following the acquisition of the FDA-approved breast cancer treatment, VEPPANU. The community is actively discussing the potential for a short squeeze given the high short interest and limited float, while closely monitoring the company's profitability and upcoming commercial launch milestones.

Vertiv Holdings Co. engages in the design, manufacture, and service of critical digital infrastructure technology for data centers, communication networks, and commercial and industrial environments. The firm also offers power management products, switchgear and busbar products, thermal management products, integrated rack systems, modular solutions, and management systems for monitoring and controlling digital infrastructure. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa (EMEA). The Americas segment includes products and services sold for applications within the data center, communication networks and commercial and industrial markets in North America and Latin America. The Asia Pacific segment consists of products and services sold for applications within the data center, communication networks and commercial and industrial markets throughout Greater China, Asia, and India. The EMEA segment focuses on products and services sold for applications within the data center, communication networks, and commercial and industrial markets in Europe, Middle East, and Africa. The company was founded in 1946 and is headquartered in Westerville, OH.

Vertiv Holdings Co - Ordinary Shares - Class A

Vertiv Holdings Co

Vertiv Holdings is facing significant downward pressure following a revenue miss in its latest earnings report, despite the company raising its full-year guidance and reaffirming strong demand for AI infrastructure. Community sentiment remains polarized, with many investors viewing the dip as a high-conviction buying opportunity supported by a massive backlog, while others express concern over the stock's premium valuation and susceptibility to broader AI-spending volatility.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is at the center of intense debate ahead of its earnings, with investors focused on whether strong AWS cloud revenue and AI demand can justify the massive capital expenditure fueling the company's data center expansion. The market remains volatile as traders weigh these long-term infrastructure investments against short-term margin pressures, making upcoming earnings guidance a critical catalyst for the stock's direction.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is trending as investors react to heightened geopolitical tensions in the Middle East and mixed earnings reports from major tech giants regarding AI-related capital expenditures. The community is actively debating the sustainability of the AI sector's rapid growth versus the potential for a broad market correction driven by interest rate concerns and shifting macroeconomic sentiment.

Arqit Quantum, Inc. engages in the provision of cybersecurity services via satellite and terrestrial forms. Its product is QuantumCloud which secures devices with cloud-based quantum encryption. The company was founded by David John Williams and David James Bestwick on April 26, 2021 and is headquartered in London, the United Kingdom.

Arqit Quantum Inc

Arqit Quantum is trending as investors speculate on a short squeeze fueled by an exceptionally low float, high institutional ownership, and significant short interest. The community is actively discussing the stock's potential for a parabolic reversal driven by its focus on post-quantum cryptography, recent government executive orders on quantum security, and key partnerships with major technology firms.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending as investors react to a significant debt repurchase and prepare for upcoming European regulatory updates. The community is actively discussing the stock's potential valuation shift, the impact of commercial catalysts like J-code implementation, and the influence of strategic partnerships on the company's financial stability.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is attracting significant attention after securing a record $266 million contract with the U.S. Space Force for 12 suborbital launches, a major catalyst that has energized discussions around its long-term growth and backlog. Despite this positive news, community sentiment remains divided between bulls focused on the company's expanding launch infrastructure in Alaska and bears pointing to broader market volatility and sensitivity to interest rate concerns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ardent Health, Inc. (ARDT) Expected to Beat Earnings Estimates: Should You Buy?

Ardent Health, Inc. (ARDT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CareDx (CDNA) Earnings Expected to Grow: Should You Buy?

CareDx (CDNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CareDx (CDNA) Moves 35.6% Higher: Will This Strength Last?

CareDx (CDNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Why Is CareDx Stock Skyrocketing Thursday?

CareDx ($CDNA) shares surge 28% as Medicare finalizes continued coverage for its kidney, heart, and lung transplant tests.read more...

CareDx to Report Second Quarter 2026 Financial Results on July 30, 2026

CareDx, Inc. (Nasdaq: CDNA) a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced it will report financial results for the second quarter 2026 after market close on Thursday, July 30, 2026. The Company will host a webcast and...

CareDx Announces Finalization of Solid Organ Transplant Molecular Testing Local Coverage Determination

CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced the finalization of the Medicare Local Coverage Determination (LCD) process related to molecular testing for solid organ allograft rejection. The final...

CareDx Completes Naveris Acquisition and Expands Oncology Reach

CDNA closes its Naveris buyout, adding NavDx and expanding its precision diagnostics reach into high-growth specialty oncology.

CareDx Completes Acquisition of Naveris, Extending Leadership into High-Growth Specialty Oncology

CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy today announced the successful completion of its previously announced acquisition of Naveris, following the satisfaction of all closing conditions. The transaction terms...

CareDx Announces Completion of Sale of Lab Products Business to Eurobio Scientific

CareDx, Inc. (Nasdaq: CDNA) The Transplant Company, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, highvalue healthcare solutions for transplant patients and caregivers, today announced the closing of the previously...

CareDx's CEO Sells 17K Shares

Key PointsThe CEO sold 17,683 shares for a transaction value of approximately ~$425,000 at a weighted average of around $24.03 per share on June 15...

CareDx, Inc. operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. Its products include AlloMap, AlloSure and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.

Caredx Inc

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$35.41
Prev Close	$35.75
Open	$35.77
Dividend Yield	0.00%
50-Day Moving Average	$27.52
Beta	1.49
Avg. Volume	969,562.27
PE Ratio	-229.79

52-Week High	$40.47
52-Week Low	$11.26
Market Capitalization	$1.85B
EPS (Annual)	-$0.4007
Price to Book	5.79
Revenue Per Employee	$496,477.12

Feed

News

Sentiment

Earnings

Fundamentals

Info

CDNACaredx Inc

Latest CDNA News